Logo

AstraZeneca's Lokelma (sodium zirconium cyclosilicate) Receives NMPA's Approval for Patients with Hyperkalaemia

Share this
AstraZeneca's Lokelma (sodium zirconium cyclosilicate) Receives NMPA's Approval for Patients with Hyperkalaemia

AstraZeneca's Lokelma (sodium zirconium cyclosilicate) Receives NMPA's Approval for Patients with Hyperkalaemia

Shots:

  • The approval is based on four trials assessing Lokelma vs PBO in patients with hyperkalemia treated for up to 12 months
  • The study resulted in a median time of 2.2 hours in achieving normal potassium levels in the blood- 98% achieved normal levels in 48 hours- rapid reduction of potassium in blood as early as one hour with one dose and a sustained treatment effect for up to one year- well-tolerated data
  • Lokelma is an insoluble oral powder formulation that results as a highly selective potassium-removing medicine approved in the US- EU- Canada to treat hyperkalemia and is under review in Japan with expected results in H1’20

Click here to read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca


Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions